SP-102
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 25/100
25
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Lumbosacral Radicular Pain
Conditions
Lumbosacral Radicular Pain
Trial Timeline
Jul 13, 2018 → Mar 15, 2019
NCT ID
NCT03613662About SP-102
SP-102 is a phase 2 stage product being developed by Scilex Holding for Lumbosacral Radicular Pain. The current trial status is completed. This product is registered under clinical trial identifier NCT03613662. Target conditions include Lumbosacral Radicular Pain.
What happened to similar drugs?
0 of 1 similar drugs in Lumbosacral Radicular Pain were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
12
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03613662 | Phase 2 | Completed |
Competing Products
5 competing products in Lumbosacral Radicular Pain
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| VX-548 + Placebo | Vertex Pharmaceuticals | Phase 2 | 35 |
| BIIB074 + Placebo | Biogen | Phase 2 | 32 |
| CNV1014802 + Placebo | Biogen | Phase 2 | 32 |
| BIIB074 | Biogen | Phase 2 | 24 |
| SP-102 + Placebo | Scilex Holding | Phase 3 | 30 |